IMMUNITYBIO INC (IBRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for IBRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| IBRX | Independent Director | 72 | ["served as Chief Business Development Officer for ProMetic Biosciences Ltd.","served as Chief Strategic Officer of Hepalink USA","served as Chief Executive Officer of Scientific Protein Laboratories, LLC","Vice Chairman and Chief Executive Officer at Abraxis BioScience, LLC","Vice President of Business Development at IVAX Corporation","served on the board of directors of GT BioPharma, Inc.","served on the board of directors of Verastem, Inc.","earned a juris doctor degree from Georgetown University Law School","earned a B.S. from Cornell University","extensive leadership experience","experience with and knowledge of the healthcare industry","experience serving on boards of directors of public companies"] | ["Compensation","Related Party Transaction"] | 2026 |
Biography sourced from the proxy statement filing.
Mr. Wendel has served as a member of the Board since December 2025. He served as Chief Business Development Officer for ProMetic Biosciences Ltd., a pharmaceutical development company, from April 2018 to May 2019. He also served as Chief Strategic Officer of Hepalink USA, the U.S. subsidiary of Shenzhen Hepalink Pharmaceutical Company, from July 2012 to July 2018 and as Chief Executive Officer of Scientific Protein Laboratories, LLC from December 2014 to June 2015. Prior to this, having served in roles of increasing responsibility at Abraxis BioScience, LLC, he was appointed Vice Chairman and Chief Executive Officer, overseeing the commercialization of Abraxane and leading the negotiations that culminated in the acquisition of the company by Celgene Corporation in 2010. He began his 14 years at Bristol-Myers Squibb Company (NYSE:BMY) in 1988 as in-house counsel before shifting to global business and corporate development where he served in roles of increasing responsibility. Subsequently, he was Vice President of Business Development at IVAX Corporation, and at American Pharmaceutical Partners, Inc. From November 2020 to May 2025, he served on the board of directors of GT BioPharma, Inc. (Nasdaq:GTBP), and from June 2016 through May 2021, he served on the board of directors of Verastem, Inc. (Nasdaq:VSTM). He also served as a director of ProMetic Biosciences Ltd. He earned a juris doctor degree from Georgetown University Law School, and a B.S. from Cornell University. We believe Mr. Wendel is qualified to serve as a member of the Board based on his extensive leadership experience, experience with and knowledge of the healthcare industry, and experience serving on boards of directors of public companies.